<DOC>
	<DOCNO>NCT03029429</DOCNO>
	<brief_summary>Pseudohypoparathyroidism genetic disorder limit treatment option . Patients early-onset obesity , short stature increase risk type 2 diabetes . This phase 2 clinical trial test efficacy theophylline , phosphodiesterase inhibitor , pseudohypoparathyroidism . The investigator hypothesize theophylline cause weight loss , improve glucose tolerance slow growth plate closure child young adult .</brief_summary>
	<brief_title>Theophylline Treatment Pseudohypoparathyroidism</brief_title>
	<detailed_description>Pseudohypoparathyroidism ( PHP ) rare , genetic disorder cause impaired stimulatory G protein ( Gsα ) signal downregulation gene , GNAS . The resultant hormone abnormality treat hormone replacement therapy , aspect disorder early-onset obesity premature epiphyseal closure without effective treatment option . Gsα signal essential normal hormonal function pituitary , thyroid , gonad , renal proximal tubule hypothalamus . While many result hormone deficiency treat hormone replacement therapy ( HRT ) , HRT effective therapy severe early-onset obesity short stature major feature PHP phenotype . Therefore , goal proposal test efficacy upstream therapy aim correct function two Gsα-dependent receptor responsible obesity ( melanocortin-4 receptor , MC4R ) short stature ( parathyroid hormone , PTH , receptor ) phenotype child PHP . Gsα-coupled receptor signal cascade begin increase cyclic adenosine monophosphate ( cAMP ) rapidly degrade enzyme phosphodiesterase ( PDE ) . PDE inhibitor act prolong cAMP signal decrease rate degradation . Given patient PHP reduce , completely absent , cAMP production , investigator seek test hypothesis PDE inhibitor theophylline reduce BMI , glucose intolerance , rate epiphyseal closure child PHP improve Gsα-coupled receptor signal . The investigator conduct 52-week randomized , placebo control clinical trial theophylline child young adult PHP . Theophylline non-selective PDE inhibitor generically available long history use pediatric patient , make ideal drug re-purposing youth PHP . Furthermore , pharmacokinetics theophylline well understood serum drug level easily measure . The investigator primary outcome change body mass index . Secondary outcome measure include change glucose tolerance predict final adult height . Anticipating 10 % dropout rate , investigator enroll 34 patient expect 30 patient complete study .</detailed_description>
	<mesh_term>Pseudohypoparathyroidism</mesh_term>
	<mesh_term>Pseudopseudohypoparathyroidism</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<criteria>1 . Age 2 25 year old 2 . Clinical diagnosis PHP ( per EuroPHP network classification guidelines1 ) : Presence PTH resistance ectopic classification OR brachydactyly type E plus 2 minor criterion ( TSH resistance , hormonal resistance , developmental delay , intrauterine postnatal growth retardation , obesity/overweight , specific facial feature ) 3 . Obesity ( BMI &gt; 95th percentile age/gender and/or ≥30 kg/m2 ) 1 . Use PDE inhibitor past 30 day 2 . History seizure disorder unrelated hypocalcemia 3 . History cardiac arrhythmia ( include bradycardia ) 4 . Hepatic insufficiency include cirrhosis acute hepatitis ( AST ALT &gt; 3x upper limit normal ) 5 . Congestive heart failure 6 . Current cigarette use alcohol abuse 7 . Pregnancy intention become pregnant next year 8 . Untreated hypothyroidism ( define free thyroxine low limit normal ) 9 . Active peptic ulcer disease 10 . Current use medication know effect theophylline level 11 . History hypersensitivity theophylline medication component 12 . History Major Depressive Disorder past 2 year , lifetime history suicide attempt , history suicidal behavior past month , history sever psychiatric disorder ( e.g . schizophrenia , bipolar disorder ) 13 . PHQ9 score ≥15 suicidal ideation type 4 5 ( CSSR ) past month 14 . Unable comply study procedure opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pseudohypoparathyroidism</keyword>
	<keyword>AHO</keyword>
	<keyword>Albright Hereditary Osteodystrophy</keyword>
</DOC>